| Variable | Categories | Hypophosphatemia | OR [95% CI] | p-value | |
| Yes (n = 6) n (%) | No (n = 54) n (%) | ||||
| Age (Years) | <60 | 3 (50) | 10 (18.5) | 1 | 0.095 |
| ≥60 | 3 (50) | 44 (81.5) | 4.4 [0.77 - 25.10] | ||
| Sex | Male | 4 (66.7) | 37 (68.5) | 0.92 [0.15 - 5.51] | 0.926 |
| Female | 2 (33.3) | 17 (31.5) | 1 | ||
| Medication | ARB use | 0 (0) | 5 (9.3) | Undefined | 0.999 |
| ACEI use | 1 (16.7) | 7 (13.0) | 1.34 [0.14 - 13.25] | 0.801 | |
| Diuretics use | 1 (16.7) | 4 (7.4) | 2.50 [0.23 - 26.91] | 0.450 | |
| Herbal med use | 2 (33.3) | 11 (20.4) | 1.95 [0.32 - 12.09] | 0.471 | |
| TFV prodrug | TDF | 6 (100) | 36 (66.7) | Undefined | 0.998 |
| TAF | 0 (0) | 18 (33.3) | 1 | ||
| Comorbidities | Hypertension | 1 (16.7) | 11 (20.4) | 0.78 [0.08 - 7.39] | 0.830 |
| HDV | 4 (66.7) | 16 (29.6) | 4.75 [0.79 - 28.60] | 0.089 | |
| BMI (kg/m2) | <18 | 1 (16.7) | 2 (3.7) | 5.20 [0.40 - 67.94] | 0.209 |
| ≥18 | 5 (83.3) | 52 (96.3) | 1 | ||
| Duration of TFV therapy (months) | <36 | 3 (50) | 4 (7.4) | 1 | 0.009 |
| ≥36 | 3 (50) | 50 (92.6) | 12.50 [1.88 - 83.31] | ||
| ALAT, IU/L | >35 | 3 (50) | 27 (50) | 1.00 [0.19 - 5.40] | 1.000 |
| ≤35 | 3 (50) | 27 (50) | 1 | ||
| ASAT, IU/L | >36 | 3 (50) | 26 (48.1) | 1.08 [0.20 - 5.82] | 0.931 |
| ≤36 | 3 (50) | 28 (51.9) | 1 | ||
| Hep B Viral load, IU/mL | >2000 | 2 (33.3) | 24 (45.3) | 0.60 [0.10 - 3.59] | 0.579 |
| ≤2000 | 4 (66.7) | 29 (54.7) | 1 | ||